A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

NCT02207465 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy
Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy

Interventions

RADIATION: Radiotherapy
DRUG: Abraxane

Sponsor

Abramson Cancer Center at Penn Medicine